NF2 and Vestibular schwannoma: A multicenter, prospective study of 22 NF2 patients (15 adult; 7 pediatric) also evaluated the efficacy and toxicity of bevacizumab for vestibular schwannoma at a higher dosage (10 mg/kg every two weeks for six months) [31].